Do you recommend altered fractionation when using cetuximab with head and neck RT?

The 5-year update of the randomized study of RT vs RT and cetuximab for HN cancer added additional factors related to better outcome in patients receiving cetuximab (in addition to the findings that only oropharyngeal cancer benefited, published previously in the NEJM paper). The additional factors ...

I think we have to, given it is cetuximab

For more information on altered fractionation and systemic therapy see reference below:

Summary of major radiation fractionation and chemotherapy trials for organ preservation therapy in locally advanced head and neck squamous cell carcinoma. Parsons JT, Greene BD., Pract Radiat Oncol. 2015 Sep-Oct;5...

I agree with @Dr. First Last's answer. No compelling evidence for hyperfractionation with CTXmab. And acute toxicity may be increased.